- Home
- EVAC vs AQST Comparison
EVAC vs AQST Comparison
Compare EVAC & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.09
HOLD
Current Price
$4.15
Company Overview
Basic Information| Metric | EVAC | AQST |
|---|---|---|
| Founded | 2024 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.3M | 521.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | EVAC | AQST |
|---|---|---|
| Price | $10.09 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 32.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $9.90 | $2.20 |
| 52 Week High | $10.17 | $7.55 |
Technical Indicators
Market Signals| Indicator | EVAC | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 51.67 |
| Support Level | $9.99 | $3.70 |
| Resistance Level | $10.17 | $4.42 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 85.71 | 68.14 |
Price Performance
Historical Comparison EVAC
AQST
About EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares
EQV Ventures Acquisition Corp II is a blank check company.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.